H.R. 2557 would require the Medicare program to cover a certain type of laboratory test for beneficiaries who test positive for prostate cancer. CBO estimates that H.R. 2557 would, on net, decrease direct spending by $7 million over the 2018-2027 period.
Enacting H.R. 2557 would affect direct spending; therefore, pay-as-you-go procedures apply. The legislation would not affect revenues.
CBO estimates that enacting H.R. 2557 would not increase net direct spending or on-budget deficits in any of the four consecutive 10-year periods beginning in 2028.
H.R. 2557 contains no intergovernmental or private-sector mandates as defined in the Unfunded Mandates Reform Act.
